Novartis agrees to acquire Avidity Biosciences
Novartis has announced a definitive agreement to acquire Avidity Biosciences, a move aimed at expanding its neuroscience portfolio with advanced programs targeting rare genetic neuromuscular disorders.
Avidity Biosciences | 27/10/2025 | By Dineshwori
Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock
Avidity Biosciences will use the funds, along with existing reserves, to advance late-stage clinical programmes, prepare for potential launches, expand commercial infrastructure, progress its AOC platform, and for general corporate needs.
Avidity Biosciences | 13/09/2025 | By Dineshwori | 176
Avidity Biosciences Welcomes Simona Skerjanec to its Board of Directors
Avidity Biosciences, Inc. has strengthened its leadership with the appointment of Simona Skerjanec, M.Pharm, MBA to its board of directors.
Avidity Biosciences | 16/05/2024 | By Aishwarya | 169
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy